Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2009, Pages 97-103

  Williams, E A ^a   Stimpson, J ^a   Wang, D ^b   Plummer, S ^c   Garaiova, I ^c   Barker, M E ^a   Corfe, B M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Obsidian Research Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAB4 MULTISTRAIN PROBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BIFIDUM CUL20; BIFIDOBACTERIUM LACTIS CUL34; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLATULENCE; HUMAN; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS ACIDOPHILUS CUL21; LACTOBACILLUS ACIDOPHILUS CUL60; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; BIFIDOBACTERIUM; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; PLACEBOS; PROBIOTICS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649196020     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03848.x     Document Type: Article

References (26)

1. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 : 1770 98.
2. Quigley EM. Probiotics in irritable bowel syndrome: an immunomodulatory strategy? J Am Coll Nutr 2007 26 : 684S 690S.
3. Pimental M. Do antibiotics influence IBS? Am J Gastroenterol 2002 97 : 2681.
4. Dupont A. Post-infectious irritable bowel syndrome. Current Gastroenterology Reports 2007 9 : 378 84.
5. Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs 2008 17 : 117 30.
6. FAO/WHO. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. ftp://ftp.fao.org/es/esn/ food/probio_report_en.pdf : Food and Agriculture Organization of the United Nations and World Health Organization, October 2001.
7. Quigley E, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007 19 : 166 72.
8. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007 133 : 24 33.
9. Plummer S, Weaver M, Harris J, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004 7 : 59 62.
10. Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005 26 : 69 74.
11. Madden J, Plummer S, Tang J, et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 2005 5 : 1091 7.
12. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 45 : ii43 7.
13. Francis C, Morris J, Whorwell P. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997 11 : 395 402.
14. Patel S, Stason W, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005 17 : 332 40.
15. Dorn S, Kaptchuk T, Park J, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007 19 : 630 7.
16. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007 13 : 3425 9.
17. Kajander K, Myllyluoma E, Rajilíc-Stojanovíc M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008 27 : 48 57.
18. Kim H, Vazquez Roque M, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005 17 : 687 96.
19. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005 22 : 387 94.
20. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004 38 (Suppl. 6 S104 6.
21. Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004 5 : 169 74.
22. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007 26 : 475 86.
23. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005 128 : 541 51.
24. Whorwell P, Altringer L, Morel J, et al. Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. Am J Gastroenterol 2006 101 : 1581 90.
25. Sinn D, Song J, Kim H, et al. Therapeutic Effect of Lactobacillus acidophilus -SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. Dig Dis Sci 2008 53 : 2714 18, doi :.
26. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007 13 : 35 7.